Is Glaukos building a multi-franchise ophthalmology platform through Epioxa and glaucoma implants?
Glaukos heads to ASCRS 2026 with Epioxa and glaucoma data. Read what this could change for keratoconus, sustained therapy, and adoption.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Why Bausch + Lomb’s ASCRS 2026 data slate matters for premium IOL competition and dry eye care
Find out why Bausch + Lomb’s ASCRS 2026 data package could reshape competition in cataract surgery, dry eye care, and ophthalmology platforms.
Medical Devices & Diagnostics
Is Alcon redefining the enhanced monofocal category with Clareon TruPlus at ASCRS 2026?
Alcon launched Clareon TruPlus at ASCRS 2026. Read why the new enhanced monofocal IOL could reshape cataract lens choice.
Pharma & Biotech
Lupin closes VISUfarma deal, but can branded ophthalmology drive the next phase of growth?
Lupin has completed its VISUfarma acquisition. Read what the deal changes for European ophthalmology, specialty pharma growth, and execution risk.
Pharma & Biotech
Can Tenpoint Therapeutics’ direct-to-patient YUVEZZI program unlock wider access in the presbyopia market?
Tenpoint Therapeutics and PHIL launch YUVEZZI direct-to-patient access for presbyopia. Read what it means for affordability, uptake, and market adoption.
Pharma & Biotech
What Ocugen, Inc.’s OCU410ST milestone means for the race to treat inherited retinal blindness
Discover what Ocugen, Inc.’s OCU410ST milestone means for the future of inherited retinal blindness treatment and the race toward first approval.
Medical Devices & Diagnostics
Can smaller eyedrops improve glaucoma outcomes? Nanodropper data make the case
Nanodropper’s glaucoma study suggests microdrops may improve pressure control and reduce waste. Read what this could mean for eye care.
Pharma & Biotech
Can VeonGen Therapeutics validate VR-based endpoints as Stargardt trials move toward pivotal design
VG801 shows early vision gains in Stargardt disease. Find out what this means for gene therapy endpoints and regulatory pathways.
Pharma & Biotech
One-time gene therapy approach from Ocugen gains traction in dry AMD pipeline race
Ocugen reports positive phase 2 data for OCU410 in geographic atrophy. Learn what this means for retinal care, regulation, and future gene therapy adoption.
Pharma & Biotech
Extended-interval nAMD therapy gets a new contender as Innovent Biologics posts Phase 3 STAR data
Innovent Biologics’ efdamrofusp alfa cleared a key Phase 3 nAMD hurdle in China. Read what the STAR data could change for retinal treatment.